Literature DB >> 34420016

Exploratory Analysis of Preoperative and Postoperative Risk Stratification Tools to Identify Acute Kidney and Myocardial Injury in Patients Undergoing Surgery for Chronic Subdural Haematoma.

Daniel J Stubbs1, Benjamin M Davies2, Rowan Burnstein3, Alexis J Joannides2, Ari Ercole3.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34420016      PMCID: PMC7613591          DOI: 10.1097/ANA.0000000000000796

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.969


× No keyword cloud information.

To the Editor

Perioperative statistical risk stratification is widespread. Such tools inform intraoperative and postoperative care as part of the National Emergency Laparotomy Audit (NELA)[1]. Patients with chronic subdural haematomas (cSDH) are often elderly with significant comorbidity[2]. Despite this, there is a paucity of literature pertaining to risk stratification models in this cohort[3]. At our centre, as part of a multidisciplinary improvement initiative (the ‘Improving Care in Elderly Neurosurgery Initiative’ (ICENI)[4]) (Project ID:PRN7705) we demonstrated a significant association between postoperative complications and length of stay[2]. As a further analysis within this cohort of operated cSDH, we explore the potential of using retrospective electronic health record (EHR) data to generate prognostic statistical models for the identification of two end-organ complications (myocardial injury –troponin above the upper limit of normal and acute kidney injury (AKI) –a rise in serum creatinine of ≥ 1.5 times baseline). Outcomes were chosen based on data availability and veracity as well as clinical relevance. The integrated nature of our EHR permitted incorporation of variables reflecting intraoperative management. This enabled an exploratory analysis of models that, analogous to NELA, could be used preoperatively and updated postoperatively. Logistic regression models were built using variables available prior to (age, American society of Anesthesiologists (ASA) score, creatinine, antithrombotic use, inter-hospital transfer, pre-operative physiological state, and comorbidities), and end of (opioid dose, length of wait, time with mean arterial pressure, (MAP) <80mmHg, time with end tidal carbon dioxide (ETCO2) outside of 3-5kPa, and volatile v intravenous anaesthetic maintenance), surgery. Physiological state was encapsulated on each admission day using the electronic postoperative morbidity score (ePOMS)[5](details in supplemental digital content). Full details of variable generation are published elsewhere[2]. Missing data was handled by multiple imputation[6]. This was used in two ways. Firstly, m=40 imputed datasets were formed to permit univariable screening (carrying forward all with p <0.2) and sequential simplification of the multivariable model using pooled likelihood ratio tests (LRT). These models were subsequently internally validated using k-fold (k=10) cross-validation using a ‘fold then impute’ strategy to minimise bias[7]. Model building and LRT results are in Supplemental Digital Content. All analysis was conducted in R v3.5.3[8]. This study utilised a previously identified, retrospective cohort of 531 consecutive cases of primary operation for cSDH between October 2014 and January 2019, with appropriate outcome data[2]. 53 individuals suffered myocardial injury, 24 AKI. 69 had at least one ‘end-organ’ complication. After multivariable model building (See Supplemental Digital Content Figure S2) an admission model containing ASA, an indicator of tertiary transfer, anti-thrombotic use, and admissions ePOMS score was formed (Model 1 in Table 1). These were supplemented with significant day of surgery variables and the process repeated. The resulting model contained ASA, tertiary transfer, anti-thrombotic use, day of surgery ePOMS, intraoperative fentanyl dose, and time out of ETCO2 range (Model 2 in Table 1). Models yielded AUCs of 0.81(SD=0.01) and 0.85 (SD=0.01) after cross-validation (Supplemental Digital Content Figures S3 and S4).
Table 1

Final models built from admission variables (Model 1) and after the addition of intraoperative events (Model 2) for identifying end-organ complications (myocardial injury or acute kidney injury) in a cohort of n = 531 patients undergoing surgery for chronic subdural haematoma. AUC Model 1: 0.81(SD = 0.01), AUC Model 2: 0.85(SD=0.04) ASA = American Society of Anesthesiologists, AUC = Area under the receiver operator characteristic curve, ePOMS = Electronic postoperative morbidity score, ETCO

VariableOdds Ratio [95% Confidence Interval] p
Model 1: Preoperative model
ASA 2.188 [1.351 − 3.546]0.002
Tertiary Transfer 0.411 [0.174 − 0.975]0.044
Anti-thrombotic use 3.143 [1.726 − 5.722]<0.001
Admission ePOMS (per 1 domain increase)1.300 [1.086 − 1.544]0.004
Model 2: Postoperative model
ASA 2.091 [1.242 − 3.521]0.006
Tertiary Transfer 0.284 [0.115 − 0.706]0.007
Anti-thrombotic use 3.626 [1.903 − 6.907]<0.001
Day of Surgery ePOMS (per 1 domain increase)1.395 [1.131 − 1.720]0.002
Intraoperative Fentanyl (per 25mcg)0.839 [0.759 − 0.926]<0.001
Time outside of ETCO2 range 3-5kPa (per 10 min)1.325 [1.095 − 1.603]0.004
Our work, despite being a single centre study and lacking external validity, demonstrates the possibility of using routinely-collected data to generate statistical models for the identification of postoperative complications after cSDH surgery. The retrospective nature of our data and the limitations of diagnostic and operative coding in cSDH[2] means we have not been able to include all potentially relevant explanatory variables (e.g. severity of cSDH). This is one of many challenges in developing prognostic models in cSDH. For instance, the apparent protective association for transferred patients reflects right censoring, due to the absence of complication data after discharge from our centre. Improved data linkage between centres is required to accurately generate models to predict complications in such patients. Our pre-surgery model could be calculated in any centre as the increment in discriminatory performance in model 2, although statistically significant, is likely clinically unimportant. For example, the apparent protective association with fentanyl dose could be identifying a subset of patients, deemed able to tolerate higher doses by their anaesthetist. The increased odds seen with variation in ETCO2 could represent patients with low cardiac output or raised intracranial pressure (requiring hyperventilation). Further work in larger cohorts, with appropriately linked outcome data, is required to validate our approach and build on the exploratory analysis reported here to determine clinical utility.
  5 in total

1.  Development and Validation of an Electronic Postoperative Morbidity Score.

Authors:  Daniel J Stubbs; Jessica L Bowen; Rachel C Furness; Fay J Gilder; Roman Romero-Ortuno; Richard Biram; David K Menon; Ari Ercole
Journal:  Anesth Analg       Date:  2019-10       Impact factor: 5.108

2.  Predicting Prognosis of Patients with Chronic Subdural Hematoma: A New Scoring System.

Authors:  Churl-Su Kwon; Omar Al-Awar; Oliver Richards; Alane Izu; Givi Lengvenis
Journal:  World Neurosurg       Date:  2017-10-20       Impact factor: 2.104

3.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.

Authors:  Jonathan A C Sterne; Ian R White; John B Carlin; Michael Spratt; Patrick Royston; Michael G Kenward; Angela M Wood; James R Carpenter
Journal:  BMJ       Date:  2009-06-29

4.  Assessment of predictive performance in incomplete data by combining internal validation and multiple imputation.

Authors:  Simone Wahl; Anne-Laure Boulesteix; Astrid Zierer; Barbara Thorand; Mark A van de Wiel
Journal:  BMC Med Res Methodol       Date:  2016-10-26       Impact factor: 4.615

5.  Identification of factors associated with morbidity and postoperative length of stay in surgically managed chronic subdural haematoma using electronic health records: a retrospective cohort study.

Authors:  Daniel J Stubbs; Benjamin M Davies; Tom Bashford; Alexis J Joannides; Peter J Hutchinson; David K Menon; Ari Ercole; Rowan M Burnstein
Journal:  BMJ Open       Date:  2020-06-30       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.